CHURCHILL MANAGEMENT Corp Purchases Shares of 18,392 Hims & Hers Health, Inc. (NYSE:HIMS)

CHURCHILL MANAGEMENT Corp acquired a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 18,392 shares of the company’s stock, valued at approximately $445,000.

A number of other large investors have also made changes to their positions in HIMS. Quest Partners LLC increased its stake in Hims & Hers Health by 22.6% during the third quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock valued at $81,000 after acquiring an additional 807 shares during the period. CWM LLC grew its holdings in shares of Hims & Hers Health by 21.4% during the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after purchasing an additional 1,054 shares in the last quarter. Cadent Capital Advisors LLC increased its position in shares of Hims & Hers Health by 1.5% during the fourth quarter. Cadent Capital Advisors LLC now owns 72,160 shares of the company’s stock valued at $1,745,000 after purchasing an additional 1,060 shares during the period. Victory Capital Management Inc. raised its stake in shares of Hims & Hers Health by 6.6% in the second quarter. Victory Capital Management Inc. now owns 19,469 shares of the company’s stock valued at $393,000 after purchasing an additional 1,212 shares in the last quarter. Finally, Rockefeller Capital Management L.P. lifted its position in Hims & Hers Health by 5.8% in the third quarter. Rockefeller Capital Management L.P. now owns 33,775 shares of the company’s stock worth $622,000 after purchasing an additional 1,864 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Stock Up 0.2 %

Shares of NYSE HIMS opened at $27.91 on Friday. Hims & Hers Health, Inc. has a 12-month low of $8.14 and a 12-month high of $35.02. The firm’s 50-day simple moving average is $27.51 and its 200 day simple moving average is $21.76. The company has a market cap of $6.10 billion, a price-to-earnings ratio of 63.44 and a beta of 1.31.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. The company had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. Hims & Hers Health’s quarterly revenue was up 77.1% on a year-over-year basis. During the same period in the prior year, the business earned ($0.04) earnings per share. On average, equities analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on HIMS shares. Canaccord Genuity Group boosted their price target on shares of Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a report on Monday, December 2nd. Morgan Stanley began coverage on shares of Hims & Hers Health in a research report on Tuesday, December 17th. They issued an “overweight” rating and a $42.00 price target for the company. Citigroup downgraded Hims & Hers Health from a “neutral” rating to a “sell” rating and lifted their price objective for the company from $24.00 to $25.00 in a report on Friday, January 10th. Bank of America lowered Hims & Hers Health from a “buy” rating to an “underperform” rating and lowered their price objective for the company from $32.00 to $18.00 in a research note on Thursday, November 14th. Finally, Deutsche Bank Aktiengesellschaft boosted their price target on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research note on Wednesday, November 6th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, Hims & Hers Health currently has an average rating of “Hold” and an average target price of $25.13.

Insiders Place Their Bets

In related news, insider Soleil Boughton sold 2,339 shares of the business’s stock in a transaction that occurred on Tuesday, October 29th. The shares were sold at an average price of $23.16, for a total transaction of $54,171.24. Following the completion of the sale, the insider now directly owns 169,935 shares of the company’s stock, valued at $3,935,694.60. The trade was a 1.36 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Michael Chi sold 17,304 shares of the firm’s stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $22.00, for a total transaction of $380,688.00. Following the completion of the transaction, the insider now directly owns 193,980 shares in the company, valued at approximately $4,267,560. The trade was a 8.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,080,208 shares of company stock valued at $29,106,823. 17.71% of the stock is currently owned by corporate insiders.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.